cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor
Abstract
HDPBI30 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HDPBI30 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the HDPBI30 polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence.
2 . The polynucleotide of claim 1 which is DNA or RNA.
3 . The polynucleotide of claim 1 wherein said nucleotide sequence is at least 80% identical to that contained in SEQ ID NO:1.
4 . The polynucleotide of claim 3 wherein said nucleotide sequence comprises the HDPBI30 polypeptide encoding sequence contained in SEQ ID NO:1.
5 . The polynucleotide of SEQ ID NO: 1.
6 . A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide of claim 3 .
7 . A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a HDPBI30 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
8 . A host cell comprising the expression system of claim 7 .
9 . A process for producing a HDPBI30 polypeptide comprising culturing a host of claim 8 and under conditions sufficient for the production of said polypeptide.
10 . The process of claim 9 wherein said polypeptideis expressed at the surface of said cell.
11 . The process of claim 9 which further includes recovering the polypeptide from the culture.
12 . A process for producing a cell which produces a HDPBI30 polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 7 such that the host cell, under appropriate culture conditions, produces a HDPBI30 polypeptide.
13 . Cells produced by the process of claim 12 .
14 . A HDPBI30 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
15 . The polypeptide of claim 14 which comprises the amino acid sequence of SEQ ID NO:2.
16 . The polypeptide of SEQ ID NO: 2.
17 . A HDPBI30 polypeptide prepared by the method of claim 11 .
18 . An antibody immunospecific for the HDPBI30 polypeptide of claim 14 .
19 . A method for the treatment of a subject in need of enhanced HDPBI30 activity comprising:
(a) administering to the subject a therapeutically effective amount of an agonist to said receptor; and/or (b) providing to the subject HDPBI30 polynucleotide in a form so as to effect production of said receptor activity in vivo.
20 . A method for the treatment of a subject having need to inhibit HDPBI30 activity comprising:
(a) administering to the subject a therapeutically effective amount of an antagonist to said receptor; and/or (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said receptor; and/or (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said receptor for its ligand.
21 . A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of HDPBI30 in a subject comprising:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said HDPBI30 in the genome of said subject; and/or (b) analyzing for the presence or amount of the HDPBI30 expression in a sample derived from said subject.
22 . A method for identifying compounds which bind to HDPBI30 polypeptide comprising:
(a) contacting cells of claim 13 with a candidate compound; and (b) assessing the ability of said candidate compound to bind to said cells.
23 . The method of claim 22 which further includes determining whether the candidate compound effects a signal generated by activation of the HDPBI30 polypeptide at the surface of the cell, wherein a candidate compound which effects production of said signal is identified as an agonist.
24 . An agonist identified by the method of claim 23 .
25 . The method of claim 22 which further includes contacting said cell with a known agonist for said HDPBI30 polypeptide; and
determining whether the signal generated by said agonist is diminished in the presence of said candidate compound, wherein a candidate compound which effects a diminution in said signal is identified as an antagonist for said HDPBI30 polypeptide.
26 . An antagonist identified by the method of claim 25 .
27 . A polynucleotide consisting essentially of a DNA sequence obtainable by screening an appropriate library containing the HDPBI30 gene under stringent hybridization conditions with a probe having the sequence of Seq ID NO: 1 or a fragment thereof; and isolating said DNA sequence.
28 . A polypetide obtainable by expressing a nucleotide sequence comprising that of SEQ ID NO:1Join the waitlist — get patent alerts
Track US2001053536A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.